Zolpat-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Pantoprazole 40mg, designed for the management of gastrointestinal disorders. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation of Zolpat-D ensures prolonged therapeutic action, improving patient compliance by reducing dosing frequency. This combination is particularly beneficial in patients experiencing delayed gastric emptying accompanied by acid-related symptoms. Zolpat-D should be used under medical supervision, with attention to contraindications such as hypersensitivity to either component and caution in patients with underlying cardiac conditions due to the potential risk of QT prolongation associated with Domperidone. Adverse effects may include headache, dry mouth, and abdominal cramps. Regular monitoring is advised during prolonged therapy to ensure efficacy and safety.